Prof Robertson speaks with ecancer at ESMO 2016 about the results of the phase III FALCON trial, which found fulvestrant significantly increased progression-free survival (PFS) in women with hormone-receptor-positive advanced breast cancer, and particularly those with less aggressive lower-volume disease.
He outlines the research that led to this trial, as discussed at SABCS 2014, and explains what these results mean for care going forwards
These results were also discussed by Dr Matthew Ellis, who spoke with ecancer here.
Read the news story for more.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.